Thomas R. Chauncey

Appointments and Affiliations

 
 
VA Puget Sound Health Care System
Medical Oncology
 
Fred Hutchinson Cancer Research Center
Associate Member, Appointed: 2001
University of Washington
School of Medicine
Medicine
Oncology
Associate Professor, Appointed: 2000
Professional Headshot of Thomas R. Chauncey

Mailing Address

Marrow Transplant Unit (S-111-MTU)
VA Puget Sound Health Care System
1660 South Columbian Way
Seattle, Washington 98108
United States

Contact

Phone: (206) 764-2709
Fax: (206) 764-2851
tchaunce@u.washington.edu

Degrees

M.D., Rush Medical College, 1985.
Ph.D., University of Chicago, 1981.

Research Interests

AML increases with advancing age, yet therapeutic outcome falls with age, due both to decreased tolerance for aggressive cytotoxic therapy as well as inherent biological resistance at the cellular level. Working with laboratory studies examining cellular resistance profiles and their correlation with clinical characteristics, clinical trials have been designed to target some of these biological characteristics. Since P-glycoprotein mediated resistance is increased in AML occurring in older patients and those with relapsed disease, efforts to overcome this biological resistance have utilized compounds known to block or reverse Pgp.

Other clinical strategies being developed include alternate drug administration schedules to enhance antileukemic activity and minimize clinical toxicities, while another strategy being evaluated is consolidation with non-myeloablative allogeneic transplant during first or subsequent remissions. Non-transplant AML studies are performed in the Southwest Oncology Group (SWOG). In addition, ongoing retrospective clinical analysis of SWOG AML trials is being performed to determine clinical and biological prognostic factors for use in future trial development.

Hematopoietic stem cell transplantation investigations are aimed at improving outcome for patients with multiple myeloma, non-Hodgkin's lymphoma, and Hodgkin's disease using autologous transplant techniques. Select patients may also be candidates for autologous and non-myeloablative allogeneic transplantation performed in tandem fashion. Other efforts are
directed at improving therapeutic outcomes with better supportive care and alternative preparative regimens for patients with a variety of hematologic malignancies undergoing allogeneic transplant from matched sibling, family matched or unrelated donors.

 

Recent Publications

2014
2013
2012
2011
2010
2009
2008
2007